JP2013510883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510883A5 JP2013510883A5 JP2012539063A JP2012539063A JP2013510883A5 JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5 JP 2012539063 A JP2012539063 A JP 2012539063A JP 2012539063 A JP2012539063 A JP 2012539063A JP 2013510883 A5 JP2013510883 A5 JP 2013510883A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- moiety
- formula
- membered saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- -1 NH 2 Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 4
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 239000012069 chiral reagent Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 2
- 239000007822 coupling agent Chemical class 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 claims 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- JRCCMJGRDJTQNS-UHFFFAOYSA-N 1-azido-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(N=[N+]=[N-])CCCC2=C1 JRCCMJGRDJTQNS-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- YAYKSOJDDDOGPS-UHFFFAOYSA-O CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c(c2c3CCCC2)ccc3[O]=S(CCO)([NH3+])=O)n[o]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c(c2c3CCCC2)ccc3[O]=S(CCO)([NH3+])=O)n[o]1 YAYKSOJDDDOGPS-UHFFFAOYSA-O 0.000 description 1
- CNZMZBQTAKCCQV-QFIPXVFZSA-N CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2c(CCC[C@@H]3NS(CCOC)(=O)=O)c3ccc2)n[o]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2c(CCC[C@@H]3NS(CCOC)(=O)=O)c3ccc2)n[o]1 CNZMZBQTAKCCQV-QFIPXVFZSA-N 0.000 description 1
- HBNRRDKSYWXGOI-UHFFFAOYSA-N CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCCC3NS(C)(=O)=O)n[o]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCCC3NS(C)(=O)=O)n[o]1 HBNRRDKSYWXGOI-UHFFFAOYSA-N 0.000 description 1
- OPLZCRMHHIAIII-QFIPXVFZSA-N CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCC[C@@H]3NC(N(C2)CC2O)=O)n[o]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCC[C@@H]3NC(N(C2)CC2O)=O)n[o]1 OPLZCRMHHIAIII-QFIPXVFZSA-N 0.000 description 1
- ALWIXISWVWRUBC-WMZHIEFXSA-N CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCC[C@H]3NC(N(CC2)C[C@H]2O)=O)n[o]1 Chemical compound CC(C)Oc(c(C#N)c1)ccc1-c1nc(-c2cccc3c2CCC[C@H]3NC(N(CC2)C[C@H]2O)=O)n[o]1 ALWIXISWVWRUBC-WMZHIEFXSA-N 0.000 description 1
- QJMCZJVKZQJBLM-UHFFFAOYSA-N CC(C)Oc(ccc(-c1nc(-c2cccc3c2CCCC3NCCS(C)(=O)=O)n[o]1)c1)c1C#N Chemical compound CC(C)Oc(ccc(-c1nc(-c2cccc3c2CCCC3NCCS(C)(=O)=O)n[o]1)c1)c1C#N QJMCZJVKZQJBLM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26128209P | 2009-11-13 | 2009-11-13 | |
| US61/261,282 | 2009-11-13 | ||
| US26247409P | 2009-11-18 | 2009-11-18 | |
| US61/262,474 | 2009-11-18 | ||
| PCT/US2010/056757 WO2011060389A1 (en) | 2009-11-13 | 2010-11-15 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510883A JP2013510883A (ja) | 2013-03-28 |
| JP2013510883A5 true JP2013510883A5 (enExample) | 2014-01-09 |
| JP5988379B2 JP5988379B2 (ja) | 2016-09-07 |
Family
ID=43992104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539063A Active JP5988379B2 (ja) | 2009-11-13 | 2010-11-15 | スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8357706B2 (enExample) |
| EP (1) | EP2498611B1 (enExample) |
| JP (1) | JP5988379B2 (enExample) |
| KR (1) | KR101781233B1 (enExample) |
| CN (1) | CN102724880B (enExample) |
| AU (1) | AU2010320041B2 (enExample) |
| BR (1) | BR112012011430A8 (enExample) |
| CA (1) | CA2780433C (enExample) |
| CY (1) | CY1120427T1 (enExample) |
| DK (1) | DK2498611T3 (enExample) |
| EA (1) | EA023183B1 (enExample) |
| ES (1) | ES2665461T3 (enExample) |
| HR (1) | HRP20180527T1 (enExample) |
| HU (1) | HUE036391T2 (enExample) |
| IL (1) | IL219690B (enExample) |
| LT (1) | LT2498611T (enExample) |
| MX (1) | MX2012005562A (enExample) |
| MY (1) | MY160907A (enExample) |
| NZ (1) | NZ599913A (enExample) |
| PH (1) | PH12012500938A1 (enExample) |
| PL (1) | PL2498611T3 (enExample) |
| PT (1) | PT2498611T (enExample) |
| RS (1) | RS57070B1 (enExample) |
| SI (1) | SI2498611T1 (enExample) |
| WO (1) | WO2011060389A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61829B1 (sr) | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| RS57070B1 (sr) * | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| CN103251950B (zh) * | 2012-02-16 | 2018-10-02 | 中国人民解放军军事科学院军事医学研究院辐射医学研究所 | S1p受体调节剂防治肠型放射病及放射性肠炎的用途 |
| CA2885155C (en) | 2012-11-16 | 2021-02-16 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters |
| PT2958913T (pt) | 2013-02-20 | 2018-12-03 | Lg Chemical Ltd | Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| SI3373931T1 (sl) | 2015-11-13 | 2023-02-28 | Oppilan Pharma Ltd. | Heterociklične spojine za zdravljenje bolezni |
| CA3009428A1 (en) * | 2015-12-22 | 2017-06-29 | AbbVie Deutschland GmbH & Co. KG | Fused (hetero)cyclic compounds as s1p modulators |
| WO2017190107A1 (en) * | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| EP3492465B1 (en) * | 2016-07-22 | 2021-03-24 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | S1p1 agonist and application thereof |
| CN106749213B (zh) * | 2016-11-25 | 2019-07-02 | 济南大学 | 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用 |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| CN110256288A (zh) * | 2019-05-13 | 2019-09-20 | 苏州山青竹生物医药有限公司 | 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法 |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP4101445B1 (en) | 2020-02-06 | 2025-04-30 | Mitsubishi Tanabe Pharma Corporation | Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome |
| CN115210223B (zh) * | 2020-03-04 | 2025-03-18 | 南昌弘益药业有限公司 | 三环类化合物及其应用 |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) * | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| EP0583346A1 (en) | 1991-04-12 | 1994-02-23 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) * | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| ATE249455T1 (de) | 1998-01-23 | 2003-09-15 | Sankyo Co | Spiropiperidin-derivate |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| CA2509218C (en) * | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| EP3345895B1 (en) | 2003-04-11 | 2019-12-04 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| AU2004277947A1 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
| CN1894225A (zh) | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| JP2008531546A (ja) | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| EP1963509A4 (en) * | 2005-12-21 | 2009-07-29 | Joseph Gabriele | CATECHOLAMINE-REGULATED PROTEIN |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CN101562977A (zh) * | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| WO2008106204A1 (en) | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| AU2009258242B2 (en) | 2008-05-14 | 2015-07-16 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| AU2010319982B2 (en) | 2009-11-13 | 2016-02-04 | Receptos Llc | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| RS57070B1 (sr) | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| RS61829B1 (sr) * | 2009-11-13 | 2021-06-30 | Receptos Llc | Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze |
| JP2014530821A (ja) | 2011-10-12 | 2014-11-20 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療 |
-
2010
- 2010-11-15 RS RS20180389A patent/RS57070B1/sr unknown
- 2010-11-15 HR HRP20180527TT patent/HRP20180527T1/hr unknown
- 2010-11-15 WO PCT/US2010/056757 patent/WO2011060389A1/en not_active Ceased
- 2010-11-15 JP JP2012539063A patent/JP5988379B2/ja active Active
- 2010-11-15 US US12/946,800 patent/US8357706B2/en active Active
- 2010-11-15 EA EA201290331A patent/EA023183B1/ru not_active IP Right Cessation
- 2010-11-15 PL PL10830877T patent/PL2498611T3/pl unknown
- 2010-11-15 PH PH1/2012/500938A patent/PH12012500938A1/en unknown
- 2010-11-15 MY MYPI2012002085A patent/MY160907A/en unknown
- 2010-11-15 DK DK10830877.6T patent/DK2498611T3/en active
- 2010-11-15 MX MX2012005562A patent/MX2012005562A/es active IP Right Grant
- 2010-11-15 KR KR1020127015219A patent/KR101781233B1/ko active Active
- 2010-11-15 CA CA2780433A patent/CA2780433C/en active Active
- 2010-11-15 PT PT108308776T patent/PT2498611T/pt unknown
- 2010-11-15 ES ES10830877.6T patent/ES2665461T3/es active Active
- 2010-11-15 LT LTEP10830877.6T patent/LT2498611T/lt unknown
- 2010-11-15 HU HUE10830877A patent/HUE036391T2/hu unknown
- 2010-11-15 BR BR112012011430A patent/BR112012011430A8/pt not_active Application Discontinuation
- 2010-11-15 SI SI201031665T patent/SI2498611T1/en unknown
- 2010-11-15 CN CN201080061143.3A patent/CN102724880B/zh active Active
- 2010-11-15 AU AU2010320041A patent/AU2010320041B2/en active Active
- 2010-11-15 NZ NZ599913A patent/NZ599913A/en unknown
- 2010-11-15 EP EP10830877.6A patent/EP2498611B1/en active Active
-
2012
- 2012-05-09 IL IL219690A patent/IL219690B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,669 patent/US20130196966A1/en not_active Abandoned
-
2015
- 2015-02-27 US US14/634,439 patent/US9394264B2/en active Active
-
2018
- 2018-04-04 CY CY20181100376T patent/CY1120427T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510883A5 (enExample) | ||
| JP2013510884A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2019520416A5 (enExample) | ||
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| JP2011523412A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2011509309A5 (enExample) | ||
| JP2016503009A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2010527984A5 (enExample) | ||
| JP2007505931A5 (enExample) | ||
| JP2014517836A5 (enExample) | ||
| JP2011517697A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| JP2009040767A5 (enExample) | ||
| US6946486B2 (en) | Quaternary ammonium compounds | |
| JP2019516726A5 (enExample) |